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i-Motifs are quadruplex DNA structures formed from sequences
rich in cytosine and held together by intercalated, hemi-proto-
nated cytosine–cytosine base pairs. These sequences are prevalent
in gene promoter regions and may play a role in gene transcription.
Targeting these structures with ligands could provide a novel way
to target genetic disease but there are very few ligands which have
been shown to interact with i-motif DNA. Fluorescent intercalator
displacement (FID) assays are a simple way to screen ligands
against DNA secondary structures. Here we characterise how
thiazole orange interacts with i-motif DNA and assess its ability for
use in a FID assay. Additionally, we report FID-based ligand screen-
ing using thiazole orange against the i-motif forming sequence
from the human telomere to reveal new i-motif binding com-
pounds which have the potential for further development.
DNA sequences rich in cytosine are capable of forming
i-motifs, non-canonical quadruplex secondary structures where
two parallel stranded duplexes are held in an antiparallel
manner by the intercalation of hemiprotonated cytosine–
cytosine+ base pairs.1,2 i-Motif structures are pH-dependent,
which has led to novel uses in nanotechnology.3–5 However,
targeting the i-motif with ligands has not been well docu-
mented in the literature, mainly due to the acidic conditions
usually required to stabilise the structure and the consequent
conflicts associated with attempting to target a potentially bio-
logically-relevant structure under physiological conditions.2
Nevertheless, there has been increasing evidence to suggest
that i-motif structures can form at neutral and even slightly
alkaline pH6 depending on the sequence,7 the presence of
molecular crowding agents,8 conditions of negative super-
helicity9 and diﬀerent types of cations.10,11 Compounds which
interact with i-motif have been shown to alter gene
expression12 and alter telomerase activity,13 but studies like
these are limited and restricted by the available choice of
i-motif binding compounds.
Förster resonance energy transfer (FRET) based experi-
ments have mainly been used as a method for identifying the
eﬀects ligands have on i-motif structure.12,14,15 Although these
are well-established methods, the addition of fluorophores
to the DNA is necessary and is not only more expensive
than using unlabelled DNA, but the additional fluorophores
can aﬀect the folding and stability of the DNA secondary
structure, thus potentially aﬀecting the results obtained by
these means.16 Fluorescent intercalator displacement (FID)
assays have previously been developed to produce a low cost
and high through-put method of screening compounds
for their selectivity and aﬃnity for DNA structures such
as G-quadruplexes,17,18 triplexes,19 hairpins20 and double
stranded DNA sequences.21 An FID assay relies on a non-
covalent intercalator that fluoresces when bound to DNA but
not when competitively displaced by a ligand. This loss of fluo-
rescence can be detected by common microplate readers using
96- or 384-well plates, allowing screens to be conducted
against a large number of putative ligands with multiple DNA
structures and sequences. However, currently there are no
reported examples of FID-type assays developed for i-motif
structures. Here we disclose a FID-based method which can be
used for screening for compounds which bind i-motif DNA.
In order to develop an FID assay for i-motif DNA it was first
important to identify a suitable probe. Ideally, FID probes
need to both bind the target of interest without aﬀecting the
structure and result in a significant fluorescence change on
binding. To identify potential i-motif binding fluorescent
probes we investigated previously used probes for DNA
secondary structures:18 ethidium bromide,19,21 thiazole
orange,17,18 acridine orange,22 crystal violet23 and a pyrene
derivative24 (Fig. S1†). The potential probes were assessed
for any changes in fluorescence on addition of an i-motif
forming sequence of DNA from the human telomere
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(5′-d[TAA-CCC-TAA-CCC-TAA-CCC-TAA-CCC]-3′, hTeloC).
Probes were examined in 10 mM sodium cacodylate buﬀer at
pH 5.5, a pH at which most literature i-motif structures are
stable.2
Of the probes examined, thiazole orange (TO) demonstrated
the largest change in fluorescence on binding (Table S1†). In
the absence of DNA, TO does not show any remarkable fluo-
rescent properties but on titration of hTeloC at pH 5.5, a
significant increase in fluorescence was observed (see Fig. 1).
Further aliquots of hTeloC i-motif resulted in a steady
increase in fluorescence emission, suggesting a concentration-
depended binding event between TO and hTeloC. The experi-
ment was also performed at pH 7.4, where hTeloC is not
folded into i-motif conformation. An increase in fluorescence
was observed, but the enhancement was not as great, indica-
tive that binding to the folded structure of the i-motif is
important for fluorescence enhancement. For the other probes
examined, the fluorescent intensity did not display the
enhancement observed with TO (Fig. S2†). As a result, TO
was selected as the most suitable fluorescent probe and
characterization of binding to the i-motif was performed.
Further fluorescence experiments with TO and hTeloC across a
wider pH range (5–8, Fig. S5†), indicated a pH of 5.5–6 for
maximum fluorescence enhancement. This enhancement is
likely due to the optimal formation of hTeloC i-motif structure
at these pHs,25 consistent with binding of the folded structure.
Using UV-Vis spectroscopy, the stoichiometry of binding
between TO and hTeloC was determined using the method of
continual variation binding analysis, indicating a 2 : 1 binding
ratio of TO : hTeloC (see Fig. S7†). Binding aﬃnity between TO
and hTeloC was also determined using UV-Vis titrations.
Starting with 5 µM of hTeloC in 50 mM sodium cacodylate at
pH 5.5, small aliquots of TO were titrated in and the resulting
spectrum taken. Using the change in absorbance at 505 nm, a
hyperbolic binding curve of fraction bound versus TO concen-
tration was generated. Given the known stoichiometry, the
data was fitted with an independent two-site binding model
to give two binding constants (Kd1 = 3.7 ± 0.7 µM, Kd2 =
78 ± 13 µM, Fig. S8†). These results reveal that TO binds with
reduced aﬃnity to i-motif compared to G-quadruplex and
duplex DNA (which demonstrate Kds between 0.3 and
0.5 µM).26 Importantly, the initial fluorescence and binding
studies indicated that TO could bind i-motif DNA strongly
enough to observe good fluorescence, but weakly enough to be
displaced by another ligand.
To investigate the ability of TO to alter or influence the con-
formation of i-motif DNA, circular dichroism (CD) was used.
Experiments were performed at pH 5.5 (where most i-motif
forming sequences are stable) the transitional pH (where 50%
of the hTeloC is folded) and pH 7.4 (physiological pH). At and
below the transitional pH (pH 6 and pH 5.5 Fig. S9 and S10†)
intense positive signals are observed at 288 nm accompanied
by negative signals at 258 nm, both characteristic of DNA
folded into an i-motif conformation.27 At pH 5.5, titration of
TO into hTeloC resulted in no significant changes in the
signals, indicating the conformation remains constant on TO
binding up to 50 µM. After this, a reduction in signals were
observed, consistent with condensation of the ligand–DNA
complex (Fig. S9†).27 A similar eﬀect was observed at pH 6
(Fig. S10†). At pH 7.4 the signal at 288 nm is absent, indicating
hTeloC is no longer folded into an i-motif (Fig. S11†). At this
pH, the equilibrium is shifted towards a mixture of random
coil and hairpin.28 On addition of TO to hTeloC at pH 7.4 a
reduction in signal intensity appeared after the addition of
10 µM, after which a positive absorbance was also observed
between 300 and 320 nm, indicative of a condensation event27
rather than any changes in structure. The results from the CD
indicate that TO does not alter the conformation of hTeloC
i-motif, so is suitable for use in an i-motif displacement based
assay.
To investigate any stabilisation properties of TO, DNA
melting experiments were conducted using FRET. In addition
to the sequence from the human telomere 5′-FAM-d
[TAA-CCC-TAA-CCC-TAA-CCC-TAA-CCC]-TAMRA-3′ (hTeloCFRET)
we also examined two other previously described i-motif
forming sequences: 5′-FAM-d[TCC-CCA-CCT-TCC-CCA-CCC-
TCC-CCA-CCC-TCC-CCA]-TAMRA-3′ (c-MycCFRET), from the pro-
moter region of MYC9,15 and 5′-FAM-d[CGC-GCT-CCC-GCC-
CCC-TCT-CCC-CTC-CCC-GCG-C]-TAMRA-3′ (HIF-1αCFRET) from
the promoter region of HIF-1α.29 Melting experiments were
performed at the respective transitional pH and at pH 5.5. All
experiments showed that TO has a stabilising eﬀect on i-motif
DNA, regardless of sequence or pH (see Fig. S10–12†); increas-
ing the concentration of TO was found to increase the melting
temperature. The stabilisation eﬀect of adding TO was most
profound in DNA sequences at the transitional pH (i.e. that
were partially unfolded and inherently less stable) and
thus assay buﬀer conditions below the transitional pH are
preferred.
Initial fluorescent intercalator displacement assays were
performed using 1 μM of pre-annealed hTeloC i-motif, com-
bined with 2 μM of TO in 10 mM sodium cacodylate at pH 5.5.
After an equilibration period of 5 minutes, the sample was
titrated with candidate i-motif binding ligands and excited at
430 nm using a fluorimeter. Initial studies were performed
using known i-motif binding ligand mitoxantrone.15 On
addition of mitoxantrone, a significant loss in fluorescence
emission at 450 nm was observed, indicative of displacement
of TO from the DNA (Fig. 2a).
Fig. 1 Fluorescence emission of TO (5 µM) in the presence of 0–5 µM
hTeloC in 10 mM sodium cacodylate buﬀer at pH 5.5 (a) and pH 7.4 (b).
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By varying the concentration of ligand added, a DC50, the
concentration where 50 percent of the TO was displaced, can
be calculated from a plot of Dx against the concentration of
ligand. The results showed that the DC50 for mitoxantrone
against hTeloC, was 1.8 μM, which is consistent with it being a
moderate i-motif binding ligand.15
Next, a higher throughput screening experiment in a
384-well plate format using the TO probe and a 960 compound
library. The MicroSource library used contains a wide range of
known drugs, natural products and biologically active com-
pounds, including mitoxantrone. In the screen, 0.5 μM (1 eq.)
of pre-annealed hTeloC was mixed with 1.0 μM (2 eq.) of TO in
the sodium cacodylate buﬀer in the wells. Then 2.5 μM (5 eq.)
of the ligand from the compound library was added, mixed
and scanned on a plate reader. TO displacement (DTO) was
calculated for each compound and they were ranked according
to their DTO. Example hits are shown in Table 1.
Similar to a previous FRET melting screen,15 mitoxantrone
was found to be one of the top hits in the FID screen with TO
displacement of 86% This was followed by two bisbiguanides:
chlorhexidine and alexidine which are known surfactants30,31
and likely to be condensing the DNA in an unspecific fashion
(see ESI†). The next-best ligand in this library after mitoxan-
trone was found to be tilorone, with a DTO of 70% followed by
tobramycin with a DTO of just under 50% The remaining
ligands gave a DTO of less than 50%, indicating weaker binding
compounds which are less able to compete with TO for the
i-motif binding sites. This indicates that TO is able to act as a
threshold to eliminate weak i-motif binders. Full FID displace-
ment titrations were performed for tilorone and tobramycin
which gave a DC50 of 2.4 μM and 2.9 μM respectively. A much
weaker ligand, tyrothricin, was also measured over a concen-
tration range, but there was no significant displacement up to
5 µM, consistent with the FID screen. In the FID assay, when
tested ligands are added to the solution of TO, there are
several potential reasons for the loss of fluorescence including:
eﬀective displacement of TO, ligand-induced condensation or
precipitation and a strong absorption at approximately
450 nm. Determining the UV-Vis absorbance of any “hit” com-
pounds can be easily measured to check for false positives via
this mechanism. We examined all the hits for their UV-Vis pro-
perties and phenazopyridine (31% displacement), was found
to also have an absorption in the same region as the TO exci-
tation wavelength, indicating a possible false positive result.
Ligand binding which induces condensation cannot be discri-
minated from direct displacement in any FID assay. Likewise,
if a ligand interferes with the fluorescence of TO, this can
also mislead readings. These are inherent drawback of the
technique and any hits should also be assessed using a
diﬀerent method. Nevertheless, this assay provides a quick
Fig. 2 Example FID assay using hTeloC (1 µM), TO (2 μM) and
mitoxantrone (0–5 µM) at pH 5.5 in 10 mM sodium cacodylate buﬀer.
(a) Example raw ﬂuorescence data. (b) Displacement versus concen-
tration plot.
Table 1 Structures of the hit compounds from the FID assay and data
for interaction with hTeloC in 10 mM sodium cacodylate at pH 5.5, % dis-
placement of TO from the screening (DTO), DC50 and % binding (%Rmax)
determined by SPR
Compound DTO/% DC50/µM
%Rmax at
50 µM/%
86 1.8 2125
70 2.4 116
49 2.9 325
31 Nd 38
30 Nd 15
27 Nd NB
22 Nd NB
21 Nd 29
19 >5 7
a Tyrothricin is a mixture of cyclic peptide natural products from
Bacillus brevis.
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and inexpensive preliminary screening method for identifi-
cation of potential i-motif binding ligands.
To give an indication of how these results compare with
another method to determine binding, surface plasmon reson-
ance (SPR) was undertaken. SPR experiments were performed
using three diﬀerent immobilised DNA targets: hTeloCBiotin
(5′-biotin-[TAA-CCC-TAA-CCC-TAA-CCC-TAA-CCC]-3′), c-MycCBiotin
(5′-biotin-[CCT-TCC-CCA-CCC-TCC-CCA-CCC-TCC-CCA]-3′) and
also double stranded DNA (DSbiotin) for comparison, which com-
prised the ODN d(biotin-[GGC-ATA-GTG-CGT-GGG-CGT-TAG-C])
hybridized with its complementary strand. To compare across
a number of ligands of diﬀerent aﬃnities, a single concen-
tration (50 µM) was used to assess binding against i-motif
forming sequences. The responses were recorded at equili-
brium and compared to the predicted binding response (Rmax)
calculated with a 1 : 1 binding stoichiometry. The results for
binding to hTeloCbiotin are given in Table 1 (full Table in ESI†).
The percentage of predicted maximum response (%Rmax) is an
indicator for binding aﬃnity. Of all the compounds tested,
mitoxantrone has the highest %Rmax (2125%), followed by
tobramycin (325%) and tilorone (116%). Phenazopyridine,
amodiaquine, minocycline and tyrothricin also showed
evidence of binding at 50 µM. Harmalol and quinalizarin
did not show significant binding at this concentration
with hTeloCbiotin, but did with cMycCbiotin (Table S2†). The
SPR relative binding results are consistent with the trends
found using the FID screen, providing some validation to the
procedure.
Additional SPR experiments were performed to determine
the aﬃnity of binding of tobramycin (Fig. S16†) and tilorone
(Fig. S15†). Tobramycin was found to bind hTeloCbiotin with a
Kd of 17 ± 2.0 μM, which was with similar aﬃnity as
c-mycCbiotin with a Kd of 13 ± 1.8 μM. Given the nature of the
compound library which houses known drugs which aﬀect
traditional drug targets, it is unsurprising that tobramycin
was also found to bind double stranded DNA with a Kd of
18 ± 1.1 μM. Further assessment of tilorone by SPR was also
performed, but it was found to be significantly weaker and
because of this could not be accurately determined using the
same range of concentrations (Fig. S17†). The screen indicates
the suitability of TO as a probe for i-motif binding and has
identified several novel i-motif binding ligands. Given the
scant literature surrounding compounds which interact with
i-motif, these newly identified ligands oﬀer much promise as
leads for further development to target i-motif DNA.
Conclusions
Herein we have described the characterization of TO binding
against i-motif DNA. The compound was found to bind with a
2 : 1 stoichiometry with low micromolar dissociation constant,
making it suitable for use in a FID displacement assay. An
example screen using a library of known drugs, natural pro-
ducts and biologically active compounds identified several
new i-motif binding ligands which have potential as lead
compounds to develop in the use in the study of i-motif DNA
structure and function.
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